129 related articles for article (PubMed ID: 38551440)
1. Comparison of the Effects of Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Liver Function in Patients with Hepatitis B: A Meta-analysis.
Chen L; Jiang Q; Chen X
Altern Ther Health Med; 2024 Mar; ():. PubMed ID: 38551440
[TBL] [Abstract][Full Text] [Related]
2. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients.
He J; Guo Y; Zhang Y; Han J; Chen J; Jia Y; Ma Z; Wu J; Zhang S; Li F; Mao R; Zhang J
Infect Drug Resist; 2023; 16():3929-3941. PubMed ID: 37361938
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
Liu R; Qiao J; Zhang L; Dou Z
Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study.
Su PY; Su WW; Hsu YC; Huang SP; Yen HH
PeerJ; 2021; 9():e12527. PubMed ID: 34820208
[TBL] [Abstract][Full Text] [Related]
6. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
7. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Lim J; Choi WM; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Choi J
Liver Int; 2022 Jul; 42(7):1517-1527. PubMed ID: 35343041
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis.
Ma X; Liu S; Wang M; Wang Y; Du S; Xin Y; Xuan S
J Clin Transl Hepatol; 2021 Jun; 9(3):335-344. PubMed ID: 34221919
[TBL] [Abstract][Full Text] [Related]
10. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
[TBL] [Abstract][Full Text] [Related]
11. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
12. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
[TBL] [Abstract][Full Text] [Related]
14. HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide.
Chen CH; Jeng WJ; Hu TH; Liu YC; Wang JH; Hung CH; Lu SN; Chien RN
Dig Liver Dis; 2023 Jun; 55(6):771-777. PubMed ID: 36737315
[TBL] [Abstract][Full Text] [Related]
15. Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients.
Hou J; Ning Q; Duan Z; Chen Y; Xie Q; Zhang L; Wu S; Tang H; Li J; Lin F; Yang Y; Gong G; Luo Y; Xie S; Wang H; Mateo R; Yazdi T; Abramov F; Yee LJ; Flaherty J; Chen C; Huang Y; Zhang M; Jia J
J Clin Transl Hepatol; 2024 May; 12(5):469-480. PubMed ID: 38779514
[TBL] [Abstract][Full Text] [Related]
16. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ
Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the side effects of antivirals in chronic hepatitis B patients: a single-center experience.
Gok Sargin Z; Celik U; Dusunceli I; Ustundag Y
Acta Gastroenterol Belg; 2022; 85(4):587-592. PubMed ID: 36566368
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
Jeong J; Shin JW; Jung SW; Park EJ; Park NH
Clin Mol Hepatol; 2022 Apr; 28(2):254-264. PubMed ID: 34959261
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
Liang LY; Yip TC; Lai JC; Lam AS; Tse YK; Hui VW; Chan HL; Wong VW; Wong GL
J Med Virol; 2022 Sep; 94(9):4440-4448. PubMed ID: 35581529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
